source
- CEPI pledges up to $16.5M to advance Egyptian biotech's Ebola vaccine candidateCEPI has committed up to $16.5 million to help bring Minapharm’s Bundibugyo Ebola vaccine candidate into clinical testing. The funding will support preclinical work and an early-stage human trial…
- Osivax licenses GC Biopharma seasonal flu vaccine to develop combined OVX836-GC FLU shotOsivax has secured a non-exclusive license from GC Biopharma for its seasonal influenza vaccine, GC FLU, to pair with Osivax’s mid-phase candidate OVX836. OVX836 targets the conserved nucleoprotei…